AQST insider transaction filings

Aquestive Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen AQST transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-184Barber Daniel — President and CEO, DirectorSale (S): 25,000 @ $4.29EDGAR
2026-08-174Korczynski Sherry — Chief Commercial OfficerTax withholding (F): 2,714 @ $4.25EDGAR
2026-07-174Barber Daniel — President and CEOSale (S): 4,631 @ $4.03 · Sale (S): 20,369 @ $4.00EDGAR
2026-06-244Krop Julie — DirectorOption exercise (M): 25,000 @ $0.71 · Sale (S): 25,000 @ $5.02 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2026-06-164Barber Daniel — President and CEOSale (S): 25,000 @ $4.16EDGAR
2026-06-124Krop Julie — DirectorGrant/award (A): 50,500 (derivative) @ $0EDGAR
2026-06-124Jenkins Abigail L. — DirectorGrant/award (A): 50,500 (derivative) @ $0EDGAR
2026-06-124Cochran John — DirectorGrant/award (A): 50,500 (derivative) @ $0EDGAR
2026-06-124Taglietti Marco — DirectorGrant/award (A): 50,500 (derivative) @ $0EDGAR
2026-06-124BROWN GREGORY B — DirectorGrant/award (A): 50,500 (derivative) @ $0EDGAR
2026-06-124MORRIS TIMOTHY E — DirectorGrant/award (A): 50,500 (derivative) @ $0EDGAR
2026-06-094Korczynski Sherry — Chief Commercial OfficerTax withholding (F): 2,714 @ $0EDGAR
2026-05-194Zalewski Thomas A. — Chief Legal OfficerGrant/award (A): 100,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0EDGAR
2026-05-184Barber Daniel — President and CEOSale (S): 8,257 @ $4.29EDGAR
2026-05-184Cioffi Melina — SVP, Regulatory AffairsTax withholding (F): 1,667 @ $4.17EDGAR
2026-05-114BRAENDER LORI J — Corporate SecretaryTax withholding (F): 135,690 @ $4.23EDGAR
2026-05-074Boyd Peter E. — Chief People OfficerTax withholding (F): 56,778 @ $4.18EDGAR
2026-05-074Barber Daniel — President and CEOTax withholding (F): 335,922 @ $4.18EDGAR
2026-05-074Jung Cassie — Chief Operating OfficerTax withholding (F): 72,734 @ $4.18EDGAR
2026-05-074BRAENDER LORI J — Corporate SecretaryTax withholding (F): 76,147 @ $4.18EDGAR
2026-05-074TOTH A ERNEST JR — Chief Financial OfficerTax withholding (F): 92,652 @ $4.18EDGAR
2026-04-134Barber Daniel — President and CEOGrant/award (A): 293,100 (derivative) @ $0EDGAR
2026-04-134Boyd Peter E. — Chief People OfficerGrant/award (A): 60,000 (derivative) @ $0EDGAR
2026-04-134Jung Cassie — Chief Operating OfficerGrant/award (A): 60,000 (derivative) @ $0EDGAR
2026-04-134Korczynski Sherry — Chief Commercial OfficerGrant/award (A): 67,500 (derivative) @ $0EDGAR
2026-04-134BRAENDER LORI J — Corporate SecretaryGrant/award (A): 82,500 (derivative) @ $0EDGAR
2026-04-134TOTH A ERNEST JR — SVP, Chief Financial OfficerGrant/award (A): 82,500 (derivative) @ $0EDGAR
2026-03-114Boyd Peter E. — Chief People OfficerGrant/award (A): 80,000 @ $0 · Sale (S): 29,814 @ $4.17 · Grant/award (A): 42,500 (derivative) @ $4.29EDGAR
2026-03-114Barber Daniel — President and CEOGrant/award (A): 262,000 @ $0 · Sale (S): 180,677 @ $4.17 · Grant/award (A): 523,000 (derivative) @ $4.29EDGAR
2026-03-114BRAENDER LORI J — Chief Legal OfficerGrant/award (A): 80,000 @ $0 · Sale (S): 40,102 @ $4.17 · Grant/award (A): 50,000 (derivative) @ $4.29EDGAR
2026-03-114Cioffi Melina — SVP, Regulatory AffairsGrant/award (A): 100,000 @ $0 · Sale (S): 25,311 @ $4.17 · Grant/award (A): 75,000 (derivative) @ $4.29EDGAR
2026-03-114Korczynski Sherry — Chief Commercial OfficerGrant/award (A): 75,000 @ $0 · Sale (S): 15,741 @ $4.17 · Grant/award (A): 42,500 (derivative) @ $4.29EDGAR
2026-03-114Jung Cassie — Chief Operating OfficerGrant/award (A): 80,000 @ $0 · Sale (S): 45,791 @ $4.17 · Grant/award (A): 42,500 (derivative) @ $0EDGAR
2026-03-114Davis Matthew W. — Chief Development OfficerGrant/award (A): 50,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2026-03-114Greenhawt Matthew J. — Chief Medical OfficerGrant/award (A): 75,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $4.29EDGAR
2026-03-114TOTH A ERNEST JR — Chief Financial OfficerGrant/award (A): 95,000 @ $0 · Sale (S): 58,254 @ $4.17 · Grant/award (A): 70,000 (derivative) @ $0EDGAR
2025-12-054Boyd Peter E. — Chief People OfficerGrant/award (A): 20,000 @ $0EDGAR
2025-12-044Cioffi Melina — SVP, Regulatory AffairsTax withholding (F): 2,083 @ $5.93EDGAR
2025-11-124Davis Matthew W. — Chief Development OfficerGrant/award (A): 50,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2025-10-174Jung Cassie — Chief Operating OfficerOption exercise (M): 25,000 @ $3.10 · Sale (S): 67,575 @ $7.01 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2025-10-174Kraus Carl N — Chief Medical OfficerSale (S): 20,272 @ $7EDGAR
2025-10-174Boyd Peter E. — See RemarksSale (S): 10,000 @ $7EDGAR
2025-09-294Barber Daniel — President and CEO, DirectorSale (S): 91,343 @ $6.03EDGAR
2025-09-294Boyd Peter E. — See RemarksSale (S): 10,000 @ $6.30EDGAR
2025-09-224Barber Daniel — President and CEO, DirectorSale (S): 400 @ $6EDGAR
2025-09-084Jung Cassie — Chief Operating OfficerOption exercise (M): 25,000 @ $3.15 · Option exercise (M): 25,000 @ $0.71 · Sale (S): 62,180 @ $5 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2025-09-084Boyd Peter E. — See RemarksSale (S): 15,000 @ $5.30EDGAR
2025-08-154Korczynski Sherry — Chief Commercial OfficerGrant/award (A): 25,000 @ $0EDGAR
2025-08-124Kraus Carl N — Chief Medical OfficerTax withholding (F): 10,819 @ $3.90EDGAR
2025-06-124Krop Julie — DirectorGrant/award (A): 42,000 (derivative) @ $3.41EDGAR

Recent 8-K events — Aquestive Therapeutics, Inc.

FiledFormItems reportedSource
2026-08-118-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-108-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-108-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-138-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-308-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-208-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-048-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-268-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-028-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-098-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AQST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →